C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/12 (2006.01) A61K 31/4409 (2006.01) A61K 31/5355 (2006.01) A61P 25/18 (2006.01) C07D 401/14 (2006.01) C07D 405/12 (2006.01) C07D 413/14 (2006.01) C07D 417/14 (2006.01)
Patent
CA 2729259
1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.
Cette invention concerne des composés hétérocycliques à substitution en 1,2 qui sont des inhibiteurs de la phosphodiestérase 10. Linvention concerne également des procédés, des compositions pharmaceutiques, des préparations pharmaceutiques et lutilisation pharmaceutique des composés dans le traitement des mammifères, notamment lhomme, en cas daffections du système nerveux central (SNC) et dautres affections susceptibles daltérer la fonction du SNC. Parmi les affections susceptibles dêtre traitées figurent les affections neurologiques, neurodégénératives et psychiatriques, y compris mais non limitées à celles associées aux déficits cognitifs ou aux symptômes de la schizophrénie.
Chesworth Richard
Ripka Amy
Shapiro Gideon
Envivo Pharmaceuticals Inc.
Smart & Biggar
LandOfFree
1,2-disubstituted heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,2-disubstituted heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,2-disubstituted heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1840776